RxDoctor Payments Data

Michelle Bruno

Physician Assistant · Towson, MDNPI 1366165136

Payments from drug & device makers

$2,931in general payments, 2019–2025

Across 78 payments — averaging $37.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$528
  • Abbott$505
  • Boston Scientific$278
  • Boehringer Ingelheim$264
  • AstraZeneca$157
  • Corcept Therapeutics$125
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$2,931100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,931 in reported general payments places this provider in the 90th percentile of 2,567 physician assistant providers in Maryland.

See all physician assistant providers in Maryland

Medicare billing

Part B allowed, 2024
$116,646
Medicare patients
493
Services billed
1,619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$88,236
EntrestoSacubitril/Valsartan51$63,014
JardianceEmpagliflozin33$29,590
XareltoRivaroxaban25$27,848
Metoprolol Succinate146$1,781
Atorvastatin Calcium60$1,194
Nitroglycerin52$1,139
Rosuvastatin Calcium38$993
Ezetimibe11$743
Ranolazine ErRanolazine28$743
Amlodipine Besylate66$617
Nifedipine ErNifedipine29$579
Lisinopril60$453
Furosemide73$431
Losartan Potassium35$402

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$113$88,23696 claims
NovartisEntresto$35$63,01451 claims
Boehringer IngelheimJardiance$264$29,59033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,567 physician assistant providers in Maryland.

Other physician assistant in Towson

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →